Go to the USUHS home page

  Our products
  A to Z index
  Contact us

Biodosimetry Tools

Emergency Response Resources
  Advisory team
  Other resources

Managing Radiation Casualties
  Depleted uranium
  Potassium iodide
  Prussian blue
  Radiation patient treatment
  Managing radiological casualties
  Response to nuclear detonation
      • 1st Edition (Jan 2009)
      • 2nd Edition (Jun 2010)
  NCRP recommendations
  Consequences of nuclear warfare

Medical Effects of Ionizing Radiation
  In-person course
  Online course
  Schedule, fees, registration
  Course resources
  » What is ionizing radiation? «
  » Veterans' radiation exposure «

Product Quick List
  Exposure assessment tools

  Books/book chapters
  Contract reports
  Journal articles/supplements
  Reports/report chapters
  Scientific reports
  Special publications
  Technical reports

Register AFRRI Products

Research Programs
  Combined Injury: Radiation with
      Other Insults

  Internal Contamination and
      Metal Toxicity

  Countermeasure Development

2014 AFRRI Seminars

USU Dept. of Radiation Biology
You are here:  HOME  >  What's New  >  New collaboration will develop radiation countermeasures

New handbook guides
medical decisions in a
radiological emergency

Dept. of Homeland Security
medical experts visit AFRRI

Ceremony welcomes
new AFRRI director

Unprecedented growth marks
AFRRI director's tenure

NRC Commissioner
tours AFRRI

Special assignment:
The Vancouver Olympics

American Nuclear Society
unveils historic-landmark plaque

Historic landmark plaque
to be installed at defense lab

AFRRI receives historic
award from American
Nuclear Society

Iraq researchers
tour AFRRI

AFRRI awarded nuclear
historic landmark status

AFRRI leaders, other research
reactor experts convene
at annual conference

Research pioneer
touched lives, influenced
future of radiation science

Former AFRRI
scientific director was
pioneer in radiation research

Researchers share latest
radiation-effects findings
with military medical community

AFRRI scientific director
elected to NCRP

Scientists deliberate
on diagnostics for
partial-body irradiation

New software to aid
treatment decisions during
radiation exposure incidents

International experts on
radiation exposure assessment
to convene at AFRRI

Ceremony marks change
of director at AFRRI

FDA clears 5-AED for
human clinical studies

New collaboration
will develop radiation

Training for the unthinkable

AFRRI employees participate
in MASCAL drill

EPA awards AFRRI scientists
with highest honor

DoD commends AFRRI
for response to terrorism

Ceremony welcomes
new AFRRI director

Revised handbook expands
casualty management

Peer review validates
AFRRI research of
measuring radioprotection
by liquid chromatography

MEIR course available
on handy card-size disc

AFRRI launches software
for radiation casualty

Chernobyl liquidators'
teeth may link radiation
dose and disease

Individual exposure
takes heat in
radiation study

Russian scientists take
different path in search
for radioprotectors

New collaboration will develop radiation countermeasures

BETHESDA, Md., Oct. 26, 2005—Editor's note: This article, originally published on this site on April 15, 2005, should have described the radiation countermeasures as oral agents rather than dietary supplements. The article is republished with corrections in its entirety.

Nuclear proliferation, terrorist activity, and the distribution of nuclear and radioactive materials through underground networks make incidents involving radiation injuries increasingly likely. As explained in a recent Report to Congress, Al-Qa'ida is known to have ambitious plans to acquire or develop nuclear weapons and is receptive to outside nuclear assistance.

That group has attempted to purchase enriched uranium. Nuclear fuel-cycle and weapons-related technologies have spread to the point that additional groups may be able to obtain or produce sufficient fissile material to build radiological weapons. In view of the increasing likelihood of radiation exposure and bioterrorism, the development of fieldable radiation countermeasures is a high priority for the Department of Defense and other government agencies.

Dr. Mark H. Whitnall
Photo: D. Morse (AFRRI)
Dr. Whitnall processes blood samples to analyze changes in white blood cells caused by ionizing radiation and an anti-radiation drug. Radiation injures a body’s infection-fighting white blood cells.

Military personnel, first responders, and civilians risk having their immune systems damaged from exposure to radiation resulting from combat, terrorist attack, or nuclear accidents. Many wouldn't know their health had been compromised until screened with radiation detection devices—or until symptoms of radiation sickness surface.

"At low doses, exposure to ionizing radiation increases the risk of cancer. At higher doses, ionizing radiation injures bone marrow, causing decreases in numbers of blood cells and platelets," says Armed Forces Radiobiology Research Institute (AFRRI) scientist Mark Whitnall. The drop in white blood cells, he adds, means the immune system cannot fight off infections that normally would be harmless.

Efforts to develop pharmacological compounds that will bolster the body's immune system focus on providing a safe, cost-effective, easily stored means of ameliorating radiation injuries for large populations. Scientists are researching drugs and dietary supplements that could be given either before or after exposure.

As the leader of AFRRI's Radiation Casualty Management Team, Dr. Whitnall emphasizes there won't be a one-pill-to-cure-all solution for diverse tissue and systemic damage resulting from varying doses of radiation exposure. "A useful radiation countermeasure must be extremely safe to be used for large numbers of radiation victims or potential victims. Some of the drug candidates that have been proposed in the past have shown unacceptable toxicity."

Dr. Whitnall explains that the current treatment of choice, other than basic clinical support including antibiotics, is the off-label use of bone marrow growth factors.

"These factors have been approved by the FDA for use in chemotherapy patients to stimulate blood-forming tissue, but not yet for use as radiation countermeasures," he said. "They need to be administered under the supervision of a physician. One goal at AFRRI is to develop countermeasures that have a safety and ease-of-administration profile that would make them suitable for use without direct involvement of physicians."

Research collaboration
In pursuit of such goals, AFRRI in January launched a research collaboration with the F. Edward Hébert School of Medicine of the Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, and Humanetics Corporation of Minneapolis, MN. The collaboration aims to develop oral agents to support immune function while exploring the potential benefits for military personnel.

AFRRI scientist centrifuges blood samples in preparation for analysis on a flow cytometer.
Photo: D. Morse (AFRRI)
Vilmar Villa, of AFRRI's Radiation Casualty Management Team, centrifuges blood samples in preparation for analysis on a flow cytometer, which identifies cell types using fluorescent labels on the cell surface.

In addition to serving as a radioprotectant, such oral agents may increase the readiness and performance of troops by improving their response to a variety of challenges to their immune system. They include exposure to novel microorganisms, stress from environmental and psychological factors, military training, rapid transit through many times zones, and combat.

"The collaboration with Humanetics will allow us to explore a number of new compounds with possible nonprescription and prescription applications," explains AFRRI’s director, U.S. Army Colonel David Jarrett, M.D. "This program will expand our evaluation and possible development of radiation countermeasure candidates suitable for use in large numbers of people, with an emphasis on safety."

Humanetics, a privately held corporation, currently has several oral agents that have shown beneficial effects on the immune system. In pre-clinical research, some have shown promise as ways to counter some of the debilitating effects of radiation exposure. "We entered into a Cooperative Research and Development Agreement with Humanetics to partner our expertise in radiobiology with their background in developing oral agents with rigorous scientific testing of efficacy and safety in humans," says Colonel Jarrett.

Because hundreds or thousands of civilians living in any of the nation's large metropolitan areas could become radiation victims from a single terrorist attack, countermeasures developed by the AFRRI-USUHS-Humanetics collaboration have potential application beyond military uses. Still, Dr. Whitnall advises caution regarding hopes for finding a single cure-all for the diverse effects of ionizing radiation.

"Other agents that may be used for radiation victims, like potassium iodide (KI), chelators like Prussian blue, calcium-diethylenetriaminepentaacetate (Ca-DTPA), and zinc DTPA, are very useful in certain situations. However, they address the ingestion of specific radioactive isotopes—not the general injury caused by external exposure to ionizing radiation. For example, KI is used to prevent thyroid cancers caused by internalization of radioactive iodine. There is a pressing need to develop countermeasures to ionizing radiation that will have a general beneficial effect on blood-forming tissues and immune competence."

Dr. Whitnall explains that, at this stage, AFRRI's most advanced radiation countermeasure candidate is 5-androstenediol (5-AED). It is being developed for FDA approval as a drug under a Cooperative Research and Development Agreement with Hollis-Eden Pharmaceuticals. Also known as HE-2100 or NEUMUNE™, 5-AED has all the characteristics of a desirable countermeasure: extremely low toxicity, enhancement of survival, and stimulation of resistance to infection. It has shown extremely promising results in pre-clinical investigations, and now has entered Phase I clinical trials. An application for Investigational New Drug (IND) status will be filed in the first half of 2005.

The safety and efficacy profile of 5-AED is such that it could be used as a single therapy in a mass casualty scenario without the need for physician or medical support. This is an important consideration, because in mass casualty scenarios medical resources would be overwhelmed, leaving most victims without access to physicians or hospitals.

The countermeasures in AFRRI's research program will be developed to work in conjunction with other measures, such as antibiotics, marrow growth factors, and KI and chelators where appropriate. A combination of dietary supplements and injectable or oral prescription drugs may be used, depending on the results of ongoing research and the nature of the disaster scenario. The time required for FDA approval of any specific countermeasure is unpredictable, Dr. Whitnall adds, because of the nature of research and the drug development process.